» Articles » PMID: 33251144

A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Nov 30
PMID 33251144
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a highly malignant and aggressive cancer with high recurrence rates and mortality. Some studies have illustrated that RNA binding proteins (RBPs) were involved in the carcinogenesis and development of multiple cancers, but the roles in HCC were still unclear. We downloaded the RNA-seq and corresponding clinical information of HCC from The Cancer Genome Atlas (TCGA) database, and 330 differentially expressed RBPs were identified between normal and HCC tissues. Through series of the univariate, the least absolute shrinkage selection operator (LASSO), and the stepwise multivariate Cox regression analyses, six prognosis-related key RBPs (CNOT6, UPF3B, MRPL54, ZC3H13, IFIT5, and PPARGC1A) were screened out from DE RBPs, and a six-RBP gene risk score signature was constructed in training set. Survival analysis indicated that HCC patients with high-risk scores had significantly worse overall survival than low-risk patients, and furthermore, the signature can be used as an independent prognostic indicator. The good accuracy of this prognostic signature was confirmed by the ROC curve analysis and was further validated in the International Cancer Genome Consortium (ICGC) HCC cohort. Besides, a nomogram based on six RBP genes was established and internally validated in the TCGA cohort. Gene set enrichment analysis demonstrated some cancer-related phenotypes were significantly gathered in the high-risk group. Overall, our study first identified an RBP-related six-gene prognostic signature, which could serve as a promising prognostic biomarker and provide some potential therapeutic targets for HCC.

Citing Articles

High Expression of MRPL23 Is Associated with Poor Survival in Clear-Cell Renal Cell Carcinoma.

Podemska E, Borowczak J, Lukasik D, Grzanka D, Durslewicz J Cancers (Basel). 2024; 16(23).

PMID: 39682098 PMC: 11640366. DOI: 10.3390/cancers16233909.


Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets.

Bacon J, Jones J, Liu G, Dickinson J, Raspin K Cancer Metastasis Rev. 2024; 43(4):1119-1135.

PMID: 39354291 PMC: 11554709. DOI: 10.1007/s10555-024-10216-4.


HnRNPR-mediated UPF3B mRNA splicing drives hepatocellular carcinoma metastasis.

Wang H, Qian D, Wang J, Liu Y, Luo W, Zhang H J Adv Res. 2024; 68:257-270.

PMID: 38402949 PMC: 11785583. DOI: 10.1016/j.jare.2024.02.010.


Association of Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha Coding Variants with Hepatocellular Carcinoma Risk in the Moroccan Population: A Case-Control Study.

Tanouti I, Fellah H, El Fihry R, Zerrad C, Abounouh K, Tahiri M Asian Pac J Cancer Prev. 2023; 24(11):3689-3696.

PMID: 38019226 PMC: 10772742. DOI: 10.31557/APJCP.2023.24.11.3689.


Nonsense-Mediated mRNA Decay Factor Functions in Human Health and Disease.

Sun L, Mailliot J, Schaffitzel C Biomedicines. 2023; 11(3).

PMID: 36979701 PMC: 10045457. DOI: 10.3390/biomedicines11030722.


References
1.
Luo Y, Na Z, Slavoff S . P-Bodies: Composition, Properties, and Functions. Biochemistry. 2018; 57(17):2424-2431. PMC: 6296482. DOI: 10.1021/acs.biochem.7b01162. View

2.
Lo U, Pong R, Yang D, Gandee L, Hernandez E, Dang A . IFNγ-Induced IFIT5 Promotes Epithelial-to-Mesenchymal Transition in Prostate Cancer via miRNA Processing. Cancer Res. 2018; 79(6):1098-1112. DOI: 10.1158/0008-5472.CAN-18-2207. View

3.
Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

4.
Maragozidis P, Papanastasi E, Scutelnic D, Totomi A, Kokkori I, Zarogiannis S . Poly(A)-specific ribonuclease and Nocturnin in squamous cell lung cancer: prognostic value and impact on gene expression. Mol Cancer. 2015; 14:187. PMC: 4635609. DOI: 10.1186/s12943-015-0457-3. View

5.
. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View